Advanced NSCLC

Advances in EGFR+ NSCLC: An Interview with Prof. Oliver Gautschi

Prof. Oliver Gautschi discusses recent advances in the treatment of EGFR-mutant non-small cell lung cancer in this on-demand expert interview.

O. Gautschi

Prof. Alessandra Curioni-Fontecedro discussing approaches in metastatic PD-L1 negative NSCLC

May 04 2026

Approaches in Metastatic PD-L1 Negative NSCLC: An Interview with Prof. Alessandra Curioni-Fontecedro

Prof. Alessandra Curioni-Fontecedro discusses treatment approaches in metastatic PD-L1 negative non-small cell lung cancer in this on-demand expert interview.

Latest Advances in Frontline EGFR+ NSCLC

} 14 min

INDUSTRY SYMPOSIUM

Unlocking New Potentials in EGFR-Mutant NSCLC

} 30 min

Best Practices in Managing Adverse Events with ADCs in NSCLC

} 18 min

N. Girard

From Our Annual Summit

ILCS Sessions

ILCS 2025

Advanced NSCLC

Latest Options for Non-Oncogene Addicted Advanced NSCLC in Frontline and Beyond

} 32 min

Advanced NSCLCResectable NSCLC

ILCS 2025

Advanced NSCLC

Open Discussion on Patient Cases

} 22 min

Oct 04 2024

ILCS 2024

Patient Cases & Open Questions

} 32 min

Oct 04 2024

ILCS 2024

Advanced NSCLC

DEBATE: Balancing Efficacy, Toxicity, and Patient-Centered Care For IO Duration in NSCLC

} 33 min

G. MountziosS. Patel

Expert Insights

Webinars

Lung Cancer Review by Solange Peters, Martin Reck, Charles Rudin

Dec 18 2025

VIRTUAL ROUNDTABLE

Advanced NSCLCSCLCADCs

2025 Approvals & Highlights

} 1 h 49 min

S. PetersC. RudinM. Reck

Targeted Therapies by Oliver Gautschi, Jarushka Naidoo, Nicolas Girard

Jul 10 2025

VIRTUAL ROUNDTABLE

O. GautschiJ. NaidooN. Girard

Targeted Therapies in NSCLC

} 1h 30 min

IO in NSCLC by Solange Peters, Jordi Remon, Patrick Forde

Jun 25 2025

VIRTUAL ROUNDTABLE

P. FordeJ. RemonS. Peters

Immunotherapies in NSCLC

} 1h 47 min

The Reading Room

Articles & Research

Sep 23 2026

Zidesamtinib produced responses in 94% of ROS1 TKI-naive patients in ARROS-1

Sep 18 2026

Sevabertinib approved in the US for untreated HER2-mutant NSCLC

Sep 17 2026

Grade 3 adverse events on the FLAURA2 combination fell from 43% during induction to 14% on osimertinib alone

D. Planchard

Sep 16 2026

First-line trastuzumab deruxtecan extended median PFS to 14.3 months in HER2-mutant NSCLC

Sep 15 2026

HARMONi-2: ivonescimab extends overall survival over pembrolizumab in China

Sep 15 2026

Advanced NSCLCBiomarkersResectable NSCLC

WCLC 2026, day 4: tumour budding, BRAF class II and III, brain radiotherapy timing, and mobile CT screening

Advanced NSCLCResectable NSCLCADCs

WCLC 2026, day 3: EGFR exon 20, ROS1 and HER2 in advanced NSCLC, and 79% alive at eight years after surgery

Advanced NSCLCADCs

DESTINY-Lung04: first-line T-DXd adds six months of PFS, no interim survival gain

PAPILLON final OS: 34.3 vs 27.9 months, HR 0.87 not significant after 76% crossover

REZILIENT 3: zipalertinib plus chemotherapy adds six months of first-line PFS

ARROS-1: first-line zidesamtinib responds in over 90% of ROS1-positive NSCLC

Sep 13 2026

Advanced NSCLCADCsImmunotherapies

EVOKE-03: sacituzumab govitecan plus pembrolizumab misses both primary endpoints

G. Mountzios

Sep 13 2026

Advanced NSCLCSCLCADCs

WCLC 2026, day 2: MRI surveillance without prophylactic cranial irradiation, and two relapse trials at 13.3 and 18.5 months

Sep 12 2026

Advanced NSCLCResectable NSCLCSCLC

WCLC 2026, day 1: extended-interval and subcutaneous dosing in SCLC, and a 70% early response

Sep 09 2026

HARMONi primary analysis reports 6.8 against 4.4 months PFS for ivonescimab plus chemotherapy after EGFR TKI progression

Sep 08 2026

Pleural metastases carried worse two-year survival than contralateral lung metastases in stage M1a NSCLC

L. Hendriks

Sep 04 2026

An EGFR-SHC1 fusion resists EGFR inhibitors through its non-kinase partner

X. Le

Sep 03 2026

Akeso reports an OS benefit for ivonescimab over pembrolizumab in PD-L1-positive NSCLC

Sep 02 2026

AI-HOPE registry recruits 920 patients to build machine-learning models for metastatic NSCLC outcomes

R. FerraraL. Hendriks

Aug 29 2026

Advanced NSCLCADCs

International panel sets 55 consensus recommendations for managing Dato-DXd side effects in NSCLC

S. Saw

Industry Sponsored

Featured Sessions

Jul 20 2026

Advances in EGFR+ NSCLC: An Interview with Prof. Oliver Gautschi

Prof. Oliver Gautschi discusses recent advances in the treatment of EGFR-mutant non-small cell lung cancer in this on-demand expert interview.

O. Gautschi

May 04 2026

Approaches in Metastatic PD-L1 Negative NSCLC: An Interview with Prof. Alessandra Curioni-Fontecedro

Prof. Alessandra Curioni-Fontecedro discusses treatment approaches in metastatic PD-L1 negative non-small cell lung cancer in this on-demand expert interview.